NewsEpisurf Medical: Year-end report 1 October – 31 December 2017

Fourth quarter 2017, compared to 2016, Group

  • Gross order intake amounted to SEK 885,088 (626,306), an increase of 41,3%
  • Order backlog amounted to SEK 893,014 (325,434), an increase of 174,4%
  • 38% growth in orders for Episealer® knee implants during the quarter with 36 (26) approved orders
  • Group net sales amounted to SEK 884,088 (1,007,759)
  • Loss before tax amounted to SEK –15,547,283 (–18,454,211)
  • Loss per share (weighted average) amounted to SEK –0.51 (–0.97)

Significant events during the fourth quarter

  • Episealer® 24 months’ clinical study results accepted for publication in peer-reviewed scientific journal
  • 5 years’ follow-up of the first Episealer® patient
  • Episurf Medical reached milestone of 300 implants
  • Episurf Medical obtained another new patent in China and Australia
  • Fredrik Zetterberg appointed Head of Marketing for Episurf Medical
  • Episurf Medical’s CEO Pål Ryfors acquired shares corresponding to 3.2% of capital and 6.8% of votes from main shareholder Serendipity Ixora
  • Episurf Medical’s 100th Episealer® implant in Germany

Significant events after the fourth quarter

  • Episurf Medical signed financing agreement of up to SEK 70m subject to approval at the general meeting
  • Episurf Medical announced that the company is in the final stages of the development of an ankle implant
  • Episurf Medical received market approval in Israel and signed distribution agreement for the Israeli market

Link to the full report

For more  information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com